Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis (Abstract)

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis Exp Biol Med (Maywood) February 2018 https://pubmed.ncbi.nlm.nih.gov/29307283/ The endogenous neuropeptide opioid growth factor, chemically termed [Met5]-enkephalin, has growth inhibitory and immunomodulatory properties. Opioid growth factor is distributed widely throughout most tissues, is autocrine and paracrine produced, and interacts […]

The Long Term Suppression of Experimental Autoimmune Encephalomyelitis… (Abstract)

The Long Term Suppression of Experimental Autoimmune Encephalomyelitis by the Opioid Growth Factor and Low Dose Naltrexone The FASEB Journal 01 April 2011 https://doi.org/10.1096/fasebj.25.1_supplement.677.6  Endogenous opioid peptides play a critical role in determining the progression of experimental autoimmune encephalomyelitis (EAE), a model for Multiple Sclerosis (MS). Treatment of animals with the enkephalin Opioid Growth Factor […]

Serum [Met 5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone (Abstract)

Serum [Met 5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone Exp Biol Med (Maywood) September 2017 https://pubmed.ncbi.nlm.nih.gov/28766982/ Low-dose naltrexone is a widely used off-label therapeutic prescribed for a variety of immune-related disorders. The mechanism underlying low-dose naltrexone’s efficacy for fatigue, Crohn’s disease, fibromyalgia, and multiple sclerosis is, in part, intermittent blockade […]

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis… (Abstract)

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis Exp Biol Med (Maywood) November 2009 https://pubmed.ncbi.nlm.nih.gov/19855075/ Preclinical investigations utilizing murine experimental auto-immune encephalomyelitis (EAE), as well as clinical observations in patients with multiple sclerosis (MS), may suggest alteration of endogenous opioid systems in MS. In this study […]

Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function (Abstract)

Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function Altern Ther Health Med 05 November 2013 https://todayspractitioner.com/wp-content/uploads/2013/10/Bernard-Bihari-MD-Low-dose-Naltrexone-for-Normalizing-Immune-System-Function-athm_19_2_bihari_56_65.pdf Bernard Bihari, MD, (1931-2010) was the discoverer of the clinical effects of low-dose naltrexone (LDN) in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Dr Bihari discovered the significant […]